Welcome to our dedicated page for MetaVia news (Ticker: MTVA), a resource for investors and traders seeking the latest updates and insights on MetaVia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MetaVia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MetaVia's position in the market.
MetaVia (NASDAQ: MTVA) announced positive top-line results from its Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial demonstrated that DA-1241 (100mg) achieved statistically significant reduction in ALT levels at weeks 4 and 8, with near-significant reduction at week 16.
Key findings include statistically significant improvements in CAP Score and HbA1c levels at Week 16. The drug showed strong safety profile with mostly mild adverse events and no drug-related serious adverse events. The study involved 109 randomized patients across two parts: testing DA-1241 alone and in combination with sitagliptin.
MetaVia (Nasdaq: MTVA), a clinical-stage biotechnology company specializing in cardiometabolic diseases, has announced its participation in the upcoming Emerging Growth Conference. The company's President and CEO Hyung Heon Kim, along with CFO Marshall H. Woodworth, will deliver a company update on December 4, 2024, at 4:10 pm ET.
The presentation will include a Q&A session, with attendees able to submit questions either in advance via email or during the event. Interested parties can register online to attend the virtual conference, with additional opportunities available for private management meetings.
FAQ
What is the current stock price of MetaVia (MTVA)?
What is the market cap of MetaVia (MTVA)?
